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Original Contributions 
Xhe Clinical Usefulness of Measuring Apolipoproteins in Diabetic 
patients: A Preliminary Report* 
J. David Fachnie, MD,+ Janet McGill, MD,* Craig Foreback, PhD,§ 
and Dorothy M. Kahkonen, MD* 
A commercial assay for apolipoproteins A-l and B as well as total cholesterol, triglyceride, and high-
density lipoprotein (HDL) cholesterol was applied to 12-hour fasted serum from 24 insulin-dependent 
and 19 noninsulin-dependent diabetic persons. Women with noninsulin-dependent diabetes mellitus 
(NIDDM) had the highest levels of total cholesterol and apolipoprotein B. Apolipoprotein B values fell 
within the normal range in all patients except the NIDDM females, where four of the ten (40%) 
samples were elevated. When apolipoprotein B was elevated, total cholesterol was also elevated, over 
220 mg/dL. Apolipoprotein A-l values fell within or above the normal range in all subjects, and a 
considerable discordance was observed between apolipoprotein A-l elevations and HDL cholesterol 
elevations. 
The divergence between HDL cholesterol and apolipoprotein A-l supports the altered composition 
of HDL in the diabetic persons studied. Further study should elucidate the clinical usefulness of 
apolipoprotein measurements in diabetic patients. (Henry FordHosp MedJ 1986;34:113-6) 
When a commercial assay for apolipoproteins A-1 and B be-came available, we wondered how this additional infor-
mation could be used to evaluate risk for atherosclerosis in our 
diabetic patients. In nondiabetic persons, apolipoprotein A-l 
was claimed to better discriminate those with and without coro-
nary-artery disease than high-density lipoprotein (HDL) cho-
lesterol (1). However, in persons with noninsulin-dependent 
diabetes mellitus (NIDDM), a divergence between apolipopro-
tein A-l and HDL cholesterol suggested that such comparisons 
may yield different results in diabetic subjects (2). Our prelimi-
nary experience with measuring apolipoproteins A-l and B in 
diabetic patients and relating these measurements to commonly 
measured triglyceride, cholesterol, and HDL cholesterol is 
described. 
Materials and Methods 
In our clinic, the 43 ambulatory patients with NIDDM and 
IDDM (insulin-dependent diabetes mellitus) who donated 12-
hour fasted blood specimens had the following characteristics: 
1) IDDM female, mean age 30 years, mean BMI (body mass 
index) 26.6, N = 9; 2) IDDM male, mean age 30 years, mean 
BMI 26.7, N = 15; 3) NIDDM female, mean age 58 years, 
mean BMI 33.0, N = 9; 4) NIDDM male, mean age 56 years, 
mean BMI 27.6, N = 9; and 5) nondiabetic persons, N = 15. 
Pasting serum was assayed for triglyceride, cholesterol, and 
HDL cholesterol using standard methods (3-5). Glycosylated 
hemoglobin was mn by high pressure liquid chromatography by 
American Bio-Science Laboratories (Farmington Hills, MI). 
'Apolipoproteins A-l and B were assayed with a commercial as-
say by ligand combined with nephilometry. In this assay, apo-
•^ snry Ford Hosp Med J—Vol 34, No 2, 1986 
lipoproteins A- l and B in serum react with specific antisera 
prepared against purified apolipoproteins A-l and B. The result-
ing antigen-antibody complex increases the turbidity in the solu-
tion. A beam of collimated, monochromatic light from a laser 
source is passed through the solution, and the antigen-antibody 
complexes produce light scatter. The forward light scatter is 
measured quantitatively in relative light scatter units and is pro-
portional to the amount of antigen in the sample (6,7). 
The data were subjected to statistical analysis including com-
putation of mean, standard deviation, analysis of variance, 
paired comparison for significant results, and correlation coeffi-
cients (Pearson Product Moment) (8). 
Further evaluation of the data for clinical usefulness was made 
by comparing the total semm cholesterol, HDL cholesterol, and 
apolipoprotein A-l and B values with available reference ranges. 
Total semm cholesterol values were compared to the "moderate 
risk" for coronary-artery disease category of the Consensus 
Conference on Lowering Blood Cholesterol, ie, 75th to 90th 
percentile for the Lipid Research Clinic's Prevalence Study (9). 
Levels greater than 220 mg/dL were considered to be elevated. 
HDL cholesterol levels were compared with Framingham values 
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Fig 1—High-density lipoprotein cholesterol in IDDM and 
NIDDM patients. I = IDDM patients and II = NIDDM 
patients. 
(10). Lower HDL cholesterol was shown to increase the risk for 
coronary-artery disease. Depressed HDL cholesterol was de-
fined as less than 45 mg/dL for males and less than 55 mg/dL for 
females. Desired ranges for apolipoproteins were defined by our 
clinical laboratory as follows: 35 to 147 mg/dL for apolipopro-
tein B and 95 to 152 mg/dL for apolipoprotein A- l . Higher levels 
of apolipoprotein A-1 and lower levels of apolipoprotein B are 
supposedly related to a decreased risk for coronary-artery dis-
ease in nondiabetic persons (11-14). 
Results 
The degree of adiposity, as measured by BMI (kg/m-^ ) and 
analyzed by Student's t-test, was not significantly different be-
tween our IDDM and NIDDM subjects of the same sex. The 
glycosylated hemoglobin, an index of blood sugar control, also 
was not significantly different between groups when subjected 
to analysis of variance. 
Using analysis of variance, the mean cholesterol and 
apolipoprotein B were significantly different, p < 0.05, be-
tween diabetic subgroups (Table). A paired comparison for sig-
nificant results revealed that cholesterol was significantly greater 
in NIDDM females than in NIDDM males. Also, apolipopro-
tein B was significantly greater in NIDDM females than in 
NIDDM males, IDDM males, and IDDM females. 
Correlation coefficients between commonly measured cho-
lesterol, triglyceride, and HDL cholesterol and the apolipo-
protein measures were strongly positive: cholesterol and 
apolipoprotein B (0.832), low-density lipoprotein (LDL) 
cholesterol and apolipoprotein B (0.650), HDL cholesterol and 
apolipoprotein A-l (0.786), and triglyceride and apolipoprotein 
B (0.806). 
Total semm triglycerides were within the laboratory normal 
range (40 to 160 mg/dL) for IDDM males and females. Eleva-
tions were observed in four of eight (50%) NIDDM males and 
four of seven (57%) NIDDM females. Total semm cholesterol 
values were elevated in four of nine (44%) IDDM males, three of 
five (80%) IDDM females, two of eight (25%) NIDDM males, 
and four of eight (50%) NIDDM females. 
HDL cholesterol was low, less than 55 mg/dL, in two of four 
(50%) IDDM females and in five of seven (71%) NIDDM 
females. HDL cholesterol was low, less than 45 mg/dL, in six of 
ten (60%) IDDM males and in four of eight (50%) NIDDM 
males (Fig 1). 
Apolipoprotein B values fell within the normal range in 
almost all subjects except for NIDDM females, where four of 
ten (40%) values were elevated over 147 mg/dL. When apolipo-
protein B was elevated, total cholesterol was also elevated, over 
220 mg/dL. 
All apolipoprotein A-l values fell within or above the normal 
range (Fig 2). Elevations were observed in 11 of 15 (73%) IDDM 
males, three of eight (38%) IDDM females, seven of nine (78%) 
NIDDM males, and seven of ten (70%) NIDDM females. An 
elevation in apolipoprotein A-l was frequentiy found in the same 
subject when HDL cholesterol was not elevated. This discor-
dance was not seen in IDDM females, but was observed in six of 
Table 
Serum Cholesterol, Ti-iglyceride, HDL Cholesterol, and Apolipoproteins* 
Number of Glycosylated HDL 
Subjects Hemoglobin Cholesterol Triglycerides Cholesterol 
Apolipoproteins 
B A - l 
IDDM Male 15 10.9 (4)t 199 ± 43 107 ± 68 41.7 ± 6.0 78 ' 3() 155 ± 20 
IDDM Female 9 12.2(5) 211 ± 4 6 76 ± 17 62.0 ± 30.0 73 ± 31 161 ± 45 
NIDDM Male 9 8.8 (4) 189 ± 40 160 ± 104 45.7 ± 17.5 78.5 ± 44 180 ± 34 
NIDDM Female 10 10.6(5) 246 ± 311 180 ± 91 42.9 ± 13.7 142* ± 56 166 ± 39 
Nondiabetic 
sample l.^ 78 ± 23 153 ± 21 
Reference 
normal ranges 6-8.8 140-220 40-160 45 male 
55 female 
35 -147 95 •152 
*A1I numbers are mean ± I standard deviation in mg/dL except glycosylated hemoglobin, which is a percentage. 
tNumber inside parentheses indicates number of subjects. 
tp < 0.05. See text for explanation. 
IDDM ^ insuhn-dependent diabetes mellitus. 
NIDDM = noninsulin-dependent diabetes mellitus. 
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•ne (66%) IDDM males, three of five (60%) NIDDM females, 
f " j j^ two of six (33%) NIDDM males. 
Discussion 
The prevalence of coronary-artery disease is 1.2 to 6.6 times 
(ligher in diabetic persons than the general population (15). Ac-
curate determination of risk factors should help the physician to 
modify this poor outcome. Unfortunately, diabetes mellitus 
modifies the lipid phenotype in rather complex ways. Variables 
such as age, sex, type of diabetes mellitus, and state of diabetic 
control must be considered. Reference ranges for nondiabetic 
nersons may not have the same meaning for diabetic persons. 
Our diabetic subgroups did not differ in degree of adiposity or 
estimate of diabetes control by glycosylated hemoglobin. 
The present study represents a preliminary evaluation of 
apolipoproteins A-l and B in our metabolism clinic. The pa-
tients selected, although few, were more or less representative of 
our population of diabetic patients. 
We evaluated our data with regard to three questions: 1) What 
is the prevalence of abnormal lipid values in our sample? 2) 
What differences exist between NIDDM, IDDM, and gender? 
3) What additional information of clinical value is provided by 
measurement of apolipoproteins A-l and B? 
Many of our diabetic subjects had abnormal lipid values. Tri-
glycerides were elevated in 50%; to 57% of NIDDM subjects. 
Cholesterol was elevated in 25%) to 80% of all subjects. De-
pressed HDL cholesterol occurred in over half of all diabetic 
persons studied. 
Regarding differences between subgroups, NIDDM females 
had elevation in both cholesterol and apolipoprotein B that 
reached statistical significance. Apolipoprotein B constitutes 
the major protein component of LDL. Elevations of apolipopro-
tein B are related to the development of coronary-artery disease 
in nondiabetic persons (16). 
An excellent study by Walden et al, which included a large 
number of NIDDM and IDDM males and females compared to 
an age, sex, and weight matched control group, reported a sim-
ilar profile of elevated cholesterol, triglyceride, and depressed 
HDL cholesterol in NIDDM females (17). Apolipoproteins were 
not available in that study. Our results are consistent with the 
view that NIDDM females have a particulariy atherogenic lipid 
profile and greater risk for coronary-artery disease (18). 
When determining what addirional information of clinical 
value was provided by apolipoprotein A-1 and B measurement 
when combined with triglycerides, cholesterol, and HDL cho-
lesterol, we found a high correlation coefficient between total 
cholesterol and apolipoprotein B. Furthermore, when apo-
lipoprotein B was elevated, cholesterol was also elevated. We 
concluded that the apolipoprotein B measures reinforced but did 
not supplement the clinical impression available from choles-
terol measures alone. 
Apolipoprotein A-l is the major protein constituent of HDL. 
HDL cholesterol levels are inversely related to the risk for isch-
emic heart disease. We have previously reported lower HDL 
cholesterol levels in diabetic persons with vascular disease (19). 
Therefore, we would expect to see depressed HDL cholesterol 
levels and correspondingly depressed apolipoprotein A-l in a 
sample of putative high-risk diabetic persons. In fact, we ob-
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Fig 2—Apolipoprotein A-l in IDDM and NIDDM patients. 
I = IDDM patients and II = NIDDM patients. 
served a high correlation between HDL cholesterol and 
apolipoprotein A - l . However, the apolipoprotein A-l values 
were surprisingly high, while HDL cholesterol levels were nor-
mal or depressed. The frequent discordance between these two 
values presents a problem that demands further study. For exam-
ple, we can no longer accept the conclusion that apolipoprotein 
A-l is more useful than HDL cholesterol in identifying persons 
with coronary-artery disease (1). The conclusion may be pre-
mature or may apply only to the nondiabetic patient. 
A similar trend of elevated apolipoprotein A-l levels despite 
relatively low HDL cholesterol has been previously observed in 
NIDDM women (2). An increase in HDL triglyceride without 
alteration in HDL particle number was used to explain this diver-
gence. Other authors have also observed a divergence between 
HDL cholesterol and apolipoprotein A-l in IDDM patients (20). 
We concluded that the divergence between HDL cholesterol and 
apolipoprotein A-l supports the concept of an altered composi-
tion of HDL in the diabetic persons studied. Further inves-
tigation should focus on the composition of HDL and its 
relationship to atherosclerosis and other complications of di-
abetes mellitus. 
The available data suggest that the clinical measurement of 
apolipoprotein B in diabetic persons will reinforce but not nec-
essarily supplement the impression of coronary-artery disease 
risk provided by cholesterol alone. The measurement of 
apolipoprotein A- l , as an isolated value, may give a false im-
pression of low risk. Accordingly, we cannot recommend the 
routine clinical measurement of apolipoproteins in diabetic per-
sons at this time. 
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